Frontiers in Immunology (Jan 2025)
Therapeutic effects of platelet-derived extracellular vesicles on viral myocarditis correlate with biomolecular content
- Danielle J. Beetler,
- Danielle J. Beetler,
- Danielle J. Beetler,
- Presley Giresi,
- Damian N. Di Florio,
- Damian N. Di Florio,
- Damian N. Di Florio,
- Jessica J. Fliess,
- Elizabeth J. McCabe,
- Molly M. Watkins,
- Molly M. Watkins,
- Molly M. Watkins,
- Vivian Xu,
- Matthew E. Auda,
- Katelyn A. Bruno,
- Katelyn A. Bruno,
- Emily R. Whelan,
- Emily R. Whelan,
- Emily R. Whelan,
- Stephen P. C. Kocsis,
- Brandy H. Edenfield,
- Sierra A. Walker,
- Sierra A. Walker,
- Sierra A. Walker,
- Logan P. Macomb,
- Kevin C. Keegan,
- Angita Jain,
- Angita Jain,
- Angita Jain,
- Andrea C. Morales-Lara,
- Isha Chekuri,
- Anneliese R. Hill,
- Houssam Farres,
- Joy Wolfram,
- Joy Wolfram,
- Atta Behfar,
- Atta Behfar,
- Paul G. Stalboerger,
- Andre Terzic,
- Andre Terzic,
- Leslie T. Cooper,
- DeLisa Fairweather,
- DeLisa Fairweather,
- DeLisa Fairweather
Affiliations
- Danielle J. Beetler
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Danielle J. Beetler
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States
- Danielle J. Beetler
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States
- Presley Giresi
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Damian N. Di Florio
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Damian N. Di Florio
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States
- Damian N. Di Florio
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States
- Jessica J. Fliess
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Elizabeth J. McCabe
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Molly M. Watkins
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Molly M. Watkins
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States
- Molly M. Watkins
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States
- Vivian Xu
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Matthew E. Auda
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Katelyn A. Bruno
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Katelyn A. Bruno
- Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, United States
- Emily R. Whelan
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Emily R. Whelan
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States
- Emily R. Whelan
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States
- Stephen P. C. Kocsis
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Brandy H. Edenfield
- Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, United States
- Sierra A. Walker
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States
- Sierra A. Walker
- Center for Systems Biology, Massachusetts General Hospital, Boston, MA, United States
- Sierra A. Walker
- Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States
- Logan P. Macomb
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Kevin C. Keegan
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Angita Jain
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Angita Jain
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States
- Angita Jain
- Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, United States
- Andrea C. Morales-Lara
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Isha Chekuri
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Anneliese R. Hill
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- Houssam Farres
- Department of Vascular Surgery, Mayo Clinic, Jacksonville, FL, United States
- Joy Wolfram
- School of Chemical Engineering, The University of Queensland, Brisbane, QLD, Australia
- Joy Wolfram
- 0Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia
- Atta Behfar
- Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States
- Atta Behfar
- 1Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic Center for Regenerative Medicine, Rochester, MN, United States
- Paul G. Stalboerger
- 1Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic Center for Regenerative Medicine, Rochester, MN, United States
- Andre Terzic
- 1Van Cleve Cardiac Regenerative Medicine Program, Mayo Clinic Center for Regenerative Medicine, Rochester, MN, United States
- Andre Terzic
- 2Department of Clinical Genomics, Mayo Clinic, Rochester, MN, United States
- Leslie T. Cooper
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- DeLisa Fairweather
- Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States
- DeLisa Fairweather
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States
- DeLisa Fairweather
- 3Department of Immunology, Mayo Clinic, Jacksonville, FL, United States
- DOI
- https://doi.org/10.3389/fimmu.2024.1468969
- Journal volume & issue
-
Vol. 15
Abstract
IntroductionExtracellular vesicles (EVs) can potently inhibit inflammation yet there is a lack of understanding about the impact of donor characteristics on the efficacy of EVs. The goal of this study was to determine whether the sex and age of donor platelet-derived EVs (PEV) affected their ability to inhibit viral myocarditis.MethodsPEV, isolated from men and women of all ages, was compared to PEV obtained from women under 50 years of age, which we termed premenopausal PEV (pmPEV). Because of the protective effect of estrogen against myocardial inflammation, we hypothesized that pmPEV would be more effective than PEV at inhibiting myocarditis. We injected PEV, pmPEV, or vehicle control in a mouse model of viral myocarditis and examined histology, gene expression, protein profiles, and performed proteome and microRNA (miR) sequencing of EVs.ResultsWe found that both PEV and pmPEV significantly inhibited myocarditis; however, PEV was more effective, which was confirmed by a greater reduction of inflammatory cells and proinflammatory and profibrotic markers determined using gene expression and immunohistochemistry. Proteome and miR sequencing of EVs revealed that PEV miRs specifically targeted antiviral, Toll-like receptor (TLR)4, and inflammasome pathways known to contribute to myocarditis while pmPEV contained general immunoregulatory miRs.DiscussionThese differences in EV content corresponded to the differing anti-inflammatory effects of the two types of EVs on viral myocarditis.
Keywords